Paclitaxel has demonstrated an embryotoxic and foetotoxic effect in rabbits and has been shown to reduce fertility in rats.
Data on the use of paclitaxel in pregnant women are not available. As with any other cytotoxic agents, the use of paclitaxel during pregnancy may result in a potential hazard to the foetus and is therefore contraindicated during pregnancy.
Women of childbearing potential receiving paclitaxel should be advised to avoid becoming pregnant, and to inform the treating physician immediately should this occur. Female and male patients of fertile age, and/or their partners should use contraceptions for at least 6 months after treatment with paclitaxel. Male patients should seek advice regarding cryoconservation of sperm prior to treatment with paclitaxel because of the possibility of infertility.
It is not known whether paclitaxel is secreted into human milk.
Paclitaxel is contraindicated during breast-feeding. Breast-feeding should be discontinued before treatment with paclitaxel.